Theravance develops and markets therapies for respiratory disease and bacterial infections. Theravance announced that it would reduce costs by ending certain research lines and reducing its workforce by around 17%.
Supernus sells and develops treatments for central nervous systems diseases. In the quarter ended 2022, net earnings increased tenfold to $25 Billion.
89Bio, a biopharmaceutical company that develops drugs for metabolic and liver disorders The company sold 16.9 Million shares in March to raise approximately $275 million through a secondary offering.